Eliem Therapeutics Inc
NASDAQ:ELYM

Watchlist Manager
Eliem Therapeutics Inc Logo
Eliem Therapeutics Inc
NASDAQ:ELYM
Watchlist
Price: 3.09 USD -1.9% Market Closed
Market Cap: 207.7m USD
Section:
 

Relative Value

There is not enough data to reliably calculate the relative value of ELYM.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ELYM Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

N/A
P/S
P/S
Price to Sales
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-3.2
Median 5Y
-3.2
Industry
23.5
Forward
-1.9
More Details
3 752.1
P/OCF
P/OCF
Price to OCF
3 752.1
vs History
10
vs Industry
100
Median 3Y
3 752.1
Median 5Y
-2
Industry
21.9
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-45
Median 5Y
-7.6
Industry
24.3
More Details
0.9
P/B
P/B
Price to Book Value
0.9
vs History
29
vs Industry
61
Median 3Y
0.9
Median 5Y
0.9
Industry
3.2
More Details
N/A
EV/S
EV/S
Enterprise Value to Sales
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.1
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.1
More Details
0.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
0.2
vs History
43
vs Industry
27
Median 3Y
0.2
Median 5Y
0.2
Industry
5.9
More Details
0.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
0.2
vs History
43
vs Industry
25
Median 3Y
0.2
Median 5Y
0.2
Industry
6.2
Forward
0.2
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
21
Median 3Y
0.7
Median 5Y
0.6
Industry
7.7
More Details
3.7
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
3.7
vs History
1
vs Industry
12
Median 3Y
1.4
Median 5Y
0.9
Industry
6.3
More Details
Negative
EV/IC
EV/IC
Enterprise Value to IC
N/A
vs History
vs Industry
3
Median 3Y
-7.4
Median 5Y
-2.4
Industry
5.6
More Details

Multiples Across Competitors

ELYM Competitors Multiples
Eliem Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Eliem Therapeutics Inc
NASDAQ:ELYM
206.4m USD 0 -3.2 0.2 0.2
IL
Can Fite Biopharma Ltd
TASE:CANF
707T ILS 255 921 586.5 -17 575 047.8 -17 246 503.8 -17 208 113.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 865 457.5 -160 957.5 -195 453.7 -193 223.4
US
Abbvie Inc
NYSE:ABBV
391.9B USD 6.6 166.9 16.2 23
US
Amgen Inc
NASDAQ:AMGN
173.8B USD 4.8 24.8 18 18
US
Gilead Sciences Inc
NASDAQ:GILD
149.7B USD 5.1 18.5 12.4 12.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.8B USD 10.1 32.1 23.5 24.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 080.3 -530.8 -578 -562.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.8B USD 5.7 17.9 17.1 19.3
AU
CSL Ltd
ASX:CSL
81.5B AUD 3.5 18.2 12.4 15.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
51.2B USD 15.9 1 175.1 158.4 192.1
P/S Multiple
Revenue Growth P/S to Growth
US
Eliem Therapeutics Inc
NASDAQ:ELYM
Average P/S: 28 978 917.6
Not Available 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
255 921 586.5
140%
1 828 011.3
FR
Pharnext SCA
OTC:PNEXF
33 865 457.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.8
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.1
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.1
10%
1
US
E
Epizyme Inc
F:EPE
2 080.3
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
6%
1
AU
CSL Ltd
ASX:CSL
3.5
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
15.9
46%
0.3
P/E Multiple
Earnings Growth PEG
US
Eliem Therapeutics Inc
NASDAQ:ELYM
Average P/E: 207.6
Negative Multiple: -3.2 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 575 047.8 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 957.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
166.9
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.8
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.5
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32.1
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -530.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
10%
1.8
AU
CSL Ltd
ASX:CSL
18.2
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 175.1
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Eliem Therapeutics Inc
NASDAQ:ELYM
Average EV/EBITDA: 32.3
0.2
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 246 503.8 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 453.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.2
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.5
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -578 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
11%
1.6
AU
CSL Ltd
ASX:CSL
12.4
8%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
158.4
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Eliem Therapeutics Inc
NASDAQ:ELYM
Average EV/EBIT: 38.1
0.2
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 208 113.6 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 223.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.6
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -562.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.3
13%
1.5
AU
CSL Ltd
ASX:CSL
15.4
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
192.1
N/A N/A

See Also

Summary
ELYM intrinsic value, competitors valuation, and company profile.
DCF Valuation
ELYM stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ELYM stock valuation using valuation multiples.
Wall Street Estimates
ELYM price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ELYM stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 307,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.